• 作者：Vicente Soriano ; ^{vicenc.soriano@gmail.com} ; Luz Martin-Carbonero ; Eugenia Vispo ; Pablo Labarga ; Pablo Barreiro
• 关键词：Hepatitis C ; Hepatitis B ; Hepatitis delta ; Tenofovir ; Telaprevir ; Boceprevir ; VIH
• 刊名：Enfermedades Infecciosas y Microbiolog铆a Cl铆nica
• 出版年：2011
• 期刊代码：pca153_0213005X
• 类别：med
• 出版时间：November 2011
• 卷：29
• 期：9
• 页码：691-701
• 文件大小：455 K

Hepatic complications currently represent one of the leading reasons for medical consultations, hospitalisation, and death in the HIV-infected population. This is due to a large extent to viral hepatitis, given its disproportionate frequency in this population. Chronic hepatitis B affects 5-10%of the HIV-infected population. Vaccination has reduced the incidence of liver disease related to hepatitis-B virus (HBV), and the availability of tenofovir has dramatically improved the prognosis of HIV/HBV carriers. Delta hepatitis affects around 15%of HIV-infected individuals in Europe harbouring positive HBsAg. It has the worst prognosis, given its accelerated course to cirrhosis and the absence of successful therapy. Lastly, chronic hepatitis C is the major cause of liver disease in the HIV population. Although classically linked to persons infected parenterally (i.e., intravenous drug users), outbreaks of acute hepatitis C among homosexual men have been reported over the last decade. Treatment with pegylated interferon plus ribavirin provides a cure in less than 40%of patients. However, the introduction of new direct acting antivirals against hepatitis- C virus (HCV) (telaprevir, boceprevir) has revolutionised the field, as HAART did in 1996 in the HIV field, improving the prognosis of co-infected patients. However, interactions between these drugs and antiretroviral agents and the risk of selective resistance pose huge threats in this population.